IDENTITY FILE 01 / GHRH ANALOG
CJC-1295: Research Overview
The name is only useful when the form is clear: long-acting CJC-1295 DAC and short-acting Modified GRF (1-29) are not interchangeable records.
The short version
CJC-1295 is an experimental version of growth-hormone-releasing hormone, the signal that prompts the pituitary gland to release growth hormone. It does not supply growth hormone directly. Instead, it stimulates the body’s own GH/IGF-1 pathway. The most important naming issue is the suffix. CJC-1295 with DAC carries an albumin-binding feature designed to keep it active for days. The product often called CJC-1295 without DAC, or Modified GRF (1-29), lacks that feature and is short-acting. Treating those labels as synonyms can merge unlike exposure patterns.
Small early human studies show that long-acting CJC-1295 can raise growth hormone and IGF-1 while preserving pulsatile growth-hormone release [4][5]. That establishes pharmacology, not broad clinical benefit. The compound has no approved human indication. Evidence is limited, long-term safety remains unresolved, and material found outside regulated research can present an identity problem of its own. This page separates the molecular record from community claims.
What it is: one label, two exposure profiles
CJC-1295 is built from the first 29 amino acids of human growth-hormone-releasing factor, with four substitutions intended to resist enzymatic breakdown and stabilize the signaling structure [7]. In the DAC form, a reactive linker joins the peptide to circulating serum albumin. That albumin association slows clearance and turns the molecule into a long-acting conjugate. Preclinical work found the conjugate detectable beyond 72 hours and produced a fourfold greater growth-hormone exposure over two hours than unconjugated hGRF(1-29) in rats [7].
The no-DAC form retains the stabilizing substitutions but not the albumin-binding component. It is commonly called Modified GRF (1-29), Mod GRF 1-29, or CJC-1295 no-DAC. Those terms are close enough to create search overlap yet refer to a materially different duration. A rigorous review therefore records the exact form rather than collapsing every mention into “CJC-1295.” The distinction affects how pharmacology, adverse signals, and study timing are interpreted.
How it works
The immediate target is the growth-hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary. Receptor activation signals through the Gs/cAMP/PKA pathway, increasing synthesis and release of growth hormone. Growth hormone then promotes hepatic production of insulin-like growth factor 1, creating the downstream GH/IGF-1 response. A current review places this mechanism within the broader pharmacology of GHRH and synthetic analogues [1].
Long duration does not necessarily mean a flat hormone signal. In healthy men, continuous stimulation with the long-acting analog increased baseline and mean growth hormone while the frequency and magnitude of secretory pulses remained intact [5]. That is a mechanistic observation, not proof of improved sleep, recovery, body composition, or healthy aging. Those proposed outcomes require their own controlled endpoints. The albumin-binding design changes persistence; it does not convert pathway activation into a demonstrated clinical benefit.
What the research shows
The human evidence base is small and mainly pharmacologic. In healthy adults, studied subcutaneous exposures produced dose-dependent increases in mean growth hormone lasting at least six days and increases in IGF-1 lasting nine to eleven days; after repeated administration, IGF-1 remained above baseline for as long as 28 days, and the estimated half-life was 5.8 to 8.1 days [4]. A separate study in healthy men reported an approximately 7.5-fold increase in trough growth hormone, with mean growth hormone about 46% higher and IGF-1 about 45% higher one week later, while pulsatility was preserved [5].
A proteomic study in 11 healthy young men found changes in several circulating proteins, with an immunoglobulin/albumin-fragment signal correlating with IGF-1; the authors proposed candidate biomarkers of axis activation [3]. In GHRH-knockout mice, daily administration restored growth and increased pituitary growth-hormone messenger RNA, while less frequent schedules were progressively less effective [6]. This is animal evidence about a deficiency model, not an outcome trial in healthy people. Analytical researchers also identified CJC-1295 in an unknown seized preparation, a reminder that a label on an unregulated product does not establish identity [2].
Reported effects, cautions & safety
The reports in this paragraph are anecdotal, not clinical evidence. Research-use communities often describe deeper sleep, faster exercise recovery, gradual changes in body composition, or improved energy. They also report water retention, puffiness, tingling in the hands, injection-site reactions, flushing, fatigue, headache, and occasional changes in appetite or blood sugar. These reports are uncontrolled, can be influenced by other compounds and behavior, and do not establish cause. The frequent confusion between DAC and no-DAC forms makes comparison even less reliable.
The controlled record supports caution rather than a wellness narrative. CJC-1295 remains investigational, with early studies designed to measure hormone responses rather than long-term health outcomes [1][4]. Sustained GH/IGF-1 stimulation raises mechanism-based questions about fluid balance, glucose regulation, and growth signaling, but the limited selected literature does not quantify long-term clinical risk. The DAC/no-DAC distinction is itself a safety issue because one form was engineered for prolonged albumin binding [7]. The seized-product identification study shows that unregulated preparations can require laboratory analysis simply to determine what they contain [2].
Where it fits in Research Peptide Fundamentals
CJC-1295 is the lead identity lesson in this collection. Its aliases are not merely alternate spellings. Some designate a long-acting albumin conjugate; others designate a short-acting analog. A review that counts CJC-1295 DAC and Modified GRF (1-29) as independent confirmations may double-count related chemistry, while a review that merges their pharmacokinetics may erase a critical difference.
It also provides a useful contrast with tesamorelin. Both engage the GHRH receptor and amplify endogenous growth-hormone signaling, yet tesamorelin has an approved, population-specific indication and randomized trials in HIV-associated lipodystrophy [13][15][17]. CJC-1295 has early pharmacology and preclinical studies but no approved clinical use. Semaglutide and PT-141 sit outside the GHRH class altogether. The shared word “peptide” is therefore the broadest possible category, not a basis for comparing efficacy or safety.